title: Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.
abstract: O6-Methylguanine has been measured in peripheral blood leukocytes of 14 patients during one or more cycles of treatment with procarbazine (daily treatment for 10 days) and in 12 patients during one or more cycles of treatment with dacarbazine (single dose per cycle). Adduct formation at levels up to about 0.4 fmole/microgram DNA was detected in all procarbazine- and all but one dacarbazine-treated patients at some point after treatment. O6-Methylguanine accumulated during procarbazine treatment in a dose-related manner (mean rate of accumulation 2.8 x 10(-4) fmole/microgram DNA per mg/m2 dose) and appeared to approach a plateau by the end of the cycle (above 600 mg/m2 cumulative dose). The average rate of O6-methylguanine formation 2 hr after dacarbazine treatment was 11 +/- 8 x 10(-4) fmole/microgram DNA per mg/m2 dose. Individuals examined on more than one treatment cycle with either drug showed broadly similar methylation responses. The rate of adduct accumulation showed a nonsignificant, negative correlation with the pretreatment lymphocyte levels of the repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT) in the case of procarbazine and no correlation in the case of dacarbazine. No consistent lymphocyte AGT depletion was noted as a result of treatment with either drug. No correlation between O6-methylguanine formation and hematological toxicity was observed. In eight patients showing full remission after treatment with dacarbazine, the value of O6-methylguanine (averaged over all the cycles) was 0.252 +/- 0.120 fmole/microgram DNA while in four patients showing partial or no response it was 0.087 +/- 0.110 fmole/microgram DNA (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, Athens, Greece.
authors.forename: S A
authors.initials: SA
authors.lastname: Kyrtopoulos
authors.forename: V L
authors.initials: VL
authors.lastname: Souliotis
authors.forename: C
authors.initials: C
authors.lastname: Valavanis
authors.forename: V A
authors.initials: VA
authors.lastname: Boussiotis
authors.forename: G A
authors.initials: GA
authors.lastname: Pangalis
mesh_terms: D000818:Animals; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000097:blood / Q000187:drug effects*; D003606:Dacarbazine / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006147:Guanine / Q000031:analogs & derivatives* / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy; D011344:Procarbazine / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D013045:Species Specificity
chemical_list: D004273:DNA, Neoplasm; D011344:Procarbazine; D006147:Guanine; D003606:Dacarbazine; C008449:O-(6)-methylguanine